Royalty Pharma (RPRX) Assets Average (2020 - 2026)

Royalty Pharma has disclosed Assets Average across 7 years of filings, most recently posting $19.8 billion for Q2 2026.

• In Q2 2026, Assets Average rose 10.31% year-over-year to $19.8 billion; the TTM figure through Jun 2026 stood at $19.8 billion (up 10.31% YoY), while the FY2025 annual figure was $18.9 billion, up 9.36% from the prior year.
• Assets Average came in at $19.8 billion for Q2 2026 at Royalty Pharma, up from $19.7 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $19.8 billion in Q2 2026 to a low of $16.1 billion in Q4 2023.
• Average Assets Average over 5 years is $17.7 billion, with a median of $17.6 billion recorded in 2022.
• Year-over-year, Assets Average slipped 6.88% in 2023 and increased 12.49% in 2024.
• Over 5 years, Assets Average stood at $17.2 billion in 2022, then retreated by 6.52% to $16.1 billion in 2023, then grew by 12.49% to $18.1 billion in 2024, then gained by 7.45% to $19.5 billion in 2025, then grew by 1.71% to $19.8 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $19.8 billion in Q2 2026, $19.7 billion in Q1 2026, and $19.5 billion in Q4 2025.